Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.